Thorsten Schlomm
0000-0001-9557-4653
Publication & Citation Trends
Publications
0 total
Abstract 7224: Nuclear/cytoplasmic translocation of β-Catenin protein is a strong predictor of unfavorable patient prognosis in ERG negative but not in ERG positive prostate cancer
Cited by 0
Semantic Scholar
Abstract 5724: HMGB1 overexpression is a strong and independent prognostic feature in ERG negative prostate cancer
Cited by 0
Semantic Scholar
1489 Aberrant β-Catenin expression is related to invasive tumor growth in urothelial carcinoma of the urinary bladder
Cited by 0
Semantic Scholar
P0134 DEPECA-2 (DEfeating PEnile CAncer 2) – robot-assisted vs. open inguinal lymphadenectomy for penile cancer – a prospective randomized trial with a supporting translational program
Cited by 0
Semantic Scholar
1495 KDM6A deficiency in urine urothelial cells can be identified by immunocytochemistry and is associated with increased bladder cancer risk
Cited by 0
Semantic Scholar
Abstract 7225: TROP2 expression is abundant in primary and recurrent prostate cancer
Cited by 0
Semantic Scholar
Evaluating Tumor Quantification in Place of Proportions in Prostate Cancer: Principles of the ProQuant Group.
Cited by 1
Semantic Scholar
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer
Cited by 1
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(407)
Prostate Cancer Diagnosis and Treatment
(224)
Cancer Genomics and Diagnostics
(85)
Bladder and Urothelial Cancer Treatments
(82)
Cancer, Lipids, and Metabolism
(73)
Affiliations
Intermountain Healthcare
Ontario Institute for Cancer Research
James S. McDonnell Foundation
Oslo University Hospital
The University of Sydney